The underlying mechanisms of RAD001 treatment is based on the inhibition of AKT and mTOR phosphorylation (Figure 1), associated to up-regulation of LC3II protein in Ishikawa (IK) and HEC-1A endometrial cancer cells lines. The gene discussed is MTOR; the disease is endometrial cancer.